ICAD logo

iCAD, Inc. Stock Price

NasdaqCM:ICAD Community·US$105.6m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

ICAD Share Price Performance

US$3.87
1.53 (65.38%)
US$3.38
Fair Value
US$3.87
1.53 (65.38%)
14.5% overvalued intrinsic discount
US$3.38
Fair Value
Price US$3.87
AnalystConsensusTarget US$3.38

ICAD Community Narratives

AnalystConsensusTarget·
Fair Value US$3.38 14.5% overvalued intrinsic discount

SaaS Transition And AI Partnerships Will Expand Healthcare Reach

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
US$3.38
14.5% overvalued intrinsic discount
Revenue growth
12.31% p.a.
Profit Margin
0.0036%
Future PE
125.88kx
Share price in 2028
US$4.22

Snowflake Analysis

Flawless balance sheet with concerning outlook.

1 Risk
1 Reward

iCAD, Inc. Key Details

US$19.5m

Revenue

US$2.4m

Cost of Revenue

US$17.2m

Gross Profit

US$22.4m

Other Expenses

-US$5.2m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
-0.19
87.90%
-26.77%
0%
View Full Analysis

About ICAD

Founded
1984
Employees
66
CEO
Dana Brown
WebsiteView website
www.icadmed.com

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company’s ProFound Breast Health Suite offers solutions for?breast?cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier; and a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging, and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation based on a 2D or 3D mammogram’s collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting by algorithmically examining a woman’s breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Recent ICAD News & Updates

Recent updates

No updates